Long-term therapeutic efficacy and safety of low-dose tacrolimus (FK506) for myasthenia gravis

Journal of the Neurological Sciences

Volumn 247, Issue 1, 2006, Pages 17-20

  Tada, Masayoshi ^a   Shimohata, Takayoshi ^a   Tada, Mari ^a   Oyake, Mutsuo ^a   Igarashi, Shuichi ^a   Onodera, Osamu ^a   Naruse, Satoshi ^a   Tanaka, Keiko ^a   Tsuji, Shoji ^b   Nishizawa, Masatoyo ^a  

^a Niigata University   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

Author keywords

Adverse effects; FK506; Myasthenia gravis; Tacrolimus hydrate; Treatment

Indexed keywords

CHOLINERGIC RECEPTOR ANTIBODY; HEMOGLOBIN A1C; INTERLEUKIN 2; PREDNISOLONE; TACROLIMUS;

ADULT; AGED; ANTIBODY TITER; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEMOGLOBIN BLOOD LEVEL; HUMAN; LONG TERM CARE; LOW DRUG DOSE; LYMPHOCYTE COUNT; MYASTHENIA GRAVIS; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; SIDE EFFECT; THYMECTOMY; THYMOMA; THYMUS HYPERPLASIA; TREATMENT DURATION;

ADULT; AGED, 80 AND OVER; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MIDDLE AGED; MYASTHENIA GRAVIS; PREDNISOLONE; PROSPECTIVE STUDIES; TACROLIMUS; TIME FACTORS;

EID: 33746315222     PISSN: 0022510X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jns.2006.03.010     Document Type: Article

References (18)

1. Drachman D.B. Myasthenia gravis. N Engl J Med 330 (1994) 1797-1810
2. Pascuzzi R.M., Coslett H.B., and Johns T.R. Long-term corticosteroid treatment of myasthenia gravis: report of 116 patients. Ann Neurol 15 (1984) 291-298
3. Kino T., Hatanaka H., Hashimoto M., Nishiyama M., Goto T., Okuhara M., et al. FK-506, a novel immunosuppressant isolated from a Streptomyces: I. Fermentation, isolation, and physico-chemical and biological characteristics. J Antibiot (Tokyo) 40 (1987) 1249-1255
4. Schreiber S.L., and Crabtree G.R. The mechanism of action of cyclosporin A and FK506. Immunol Today 13 (1992) 136-142
5. Vincenti F. Tacrolimus (FK 506) in kidney transplantation: five-year survival results of the U.S. multicenter, randomized, comparative trial. Transplant Proc 33 (2001) 1019-1020
6. Gremillion R.B., Posever J.O., Manek N., West J.P., and van Volen-Hoven R.F. Tacrolimus (FK506) in the treatment of severe, refractory rheumatoid arthritis: initial experience in 12 patients. J Rheumatol 26 (1999) 2332-2336
7. Duddridge M., and Powell R.J. Treatment of severe and difficult cases of systemic lupus erythematosus with tacrolimus. A report of three cases. Ann Rheum Dis 56 (1997) 690-692
8. Yoshikawa H., Iwasa K., Satoh K., and Takamori M. FK506 prevents induction of rat experimental autoimmune myasthenia gravis. J Autoimmun 10 (1997) 11-16
9. Konishi T., Yoshiyama Y., Takamori M., Yagi K., Mukai E., and Saida T. Clinical study of FK506 in patients with myasthenia gravis. Muscle Nerve 28 (2003) 570-574
10. Konishi T., Yoshiyama Y., Takamori M., and Saida T. Long-term treatment of generalised myasthenia gravis with FK506 (tacrolimus). J Neurol Neurosurg Psychiatry 76 (2005) 448-450
11. Kawaguchi N., Yoshiyama Y., Nemoto Y., Munakata S., Fukutake T., and Hattori T. Low-dose tacrolimus treatment in thymectomised and steroid-dependent myasthenia gravis. Curr Med Res Opin 20 (2004) 1269-1273
12. Nagane Y., Utsugisawa K., Obara D., Kondoh R., and Terayama Y. Efficacy of low-dose FK506 in the treatment of myasthenia gravis-a randomized pilot study. Eur Neurol 53 (2005) 146-150
13. Ponseti J.M., Azem J., Fort J.M., Lopez-Cano M., Vilallonga R., Buera M., et al. Long-term results of tacrolimus in cyclosporine- and prednisone-dependent myasthenia gravis. Neurology 64 (2005) 1641-1643
14. Jaretzki III A., Barohn R.J., Ernstoff R.M., Kaminski H.J., Keesey J.C., Penn A.S., et al. Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America. Neurology 55 (2000) 16-23
15. Utsugisawa K., Nagane Y., Yonezawa H., Obara D., Kondoh R., and Tohgi H. Effects of FK506 on myasthenia gravis patients with high interleukin-2 productivity in peripheral blood mononuclear cells. Muscle Nerve 27 (2003) 245-248
16. Barohn R.J., McIntire D., Herbelin L., Wolfe G.I., Nations S., and Bryan W.W. Reliability testing of the quantitative myasthenia gravis score. Ann NY Acad Sci 841 (1998) 769-772
17. Gruessner R.W., Bartlett S.T., Burke G.W., and Stock P.G. Suggested guidelines for the use of tacrolimus in pancreas/kidney transplantation. Clin Transplant 12 (1998) 260-262
18. Yoshikawa H., Mabuchi K., Yasukawa Y., Takamori M., and Yamada M. Low-dose tacrolimus for intractable myasthenia gravis. J Clin Neurosci 9 (2002) 627-628